APL titers, using the notable mention of rituximab as probably the most successful drugs accessible
APL titers, using the notable mention of rituximab as probably the most successful drugs accessible in this setting. Specific longterm therapies for ITP (i.e., TPOreceptor agonists) really should be cautiously…